CAMBRIDGE, Mass., April 30 /PRNewswire-FirstCall/-- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will present
at Deutsche Bank Securities 29th Annual Healthcare Conference in Baltimore,
Maryland, May 4-5, 2004. Michael J. Astrue, President and Chief Executive
Officer will present an overview of TKT's business activities at 9:30 a.m.
Eastern Time on Wednesday, May 5, 2004. A live audio webcast of this
presentation will be available at http://www.tktx.com on TKT's Investor Information
website under the Events category. A replay will be available until May 19,
2004.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and Latin America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist, +1-617-349-0205
|
